Minneapolis-St. Paul
In February 2015, the Minnesota Department of Health Public Health Laboratory determined that 14 Shigella sonnei isolates obtained during May 13-December 8, 2014, displayed DSA (minimum inhibitory concentration >16 µg/ml).
CDC's National Antimicrobial Resistance Monitoring System laboratory performed antimicrobial susceptibility testing and polymerase chain reaction testing to identify resistance genes on 13 of these isolates. All 13 isolates 1) were susceptible to nalidixic acid and ciprofloxacin, 2) were resistant to ampicillin and trimethoprim/sulfamethoxazole, 3) displayed DSA, and 4) harbored macrolide resistance genes mphA and ermB. The 14 isolates yielded five similar PFGE patterns (Figure) .
Patients were male, had a median age of 39 years (range = 24-64 years) and lived in or near metropolitan Minneapolis-St. Paul. Patients were ill for a median of 12 days (range = 8-21 days), and one patient (7%) was hospitalized. Five were treated with ciprofloxacin, three with metronidazole, one with azithromycin, and one with an unknown antimicrobial agent. Of the four remaining patients, two were not treated with antimicrobial agents, and two had no available treatment information. Eight of nine with such information self-identified as MSM. Thirteen (93%) had received a diagnosis of sexually transmitted infection at least once during 2012-2015 (chlamydia [16 infections], gonorrhea [10] , and syphilis [2] ). Six (43%) were infected with human immunodeficiency virus (HIV); three had CD4 counts of 467, 516, and 899, respectively, in late 2014.
Chicago
During July 31-October 31, 2014, the Chicago Department of Public Health detected 23 cases of S. sonnei infection among male Chicago residents aged >17 years. Among 17 (74%) isolates that underwent PFGE analysis, 10 displayed patterns highly similar to or indistinguishable from patterns in the Minneapolis-St. Paul outbreak (Figure) and are included in this analysis. The CDC laboratory performed antimicrobial susceptibility testing on eight Chicago isolates; all eight displayed the same antimicrobial susceptibility profile as the Minneapolis-St. Paul isolates and harbored mphA and ermB. The median age of the Chicago patients was 35 years (range = 24-53 years). Seven (88%) patients self-identified as MSM among eight who provided this information, and six (60%) were infected with HIV. Five (50%) patients were hospitalized; HIV infection was not associated with hospitalization (Fisher's exact test, p = 0.5).
San Francisco and Los Angeles
Using CDC's PulseNet, investigators detected additional isolates with PFGE patterns indistinguishable from the outbreak clusters. A man aged 32 years from San Francisco who self-identified as MSM and reported no travel developed illness in January 2015 (Figure) . In addition, one PFGE pattern was associated with a previously reported 2012 outbreak of 43 cases of shigellosis with DSA in Los Angeles (Figure) (9) .
Further Laboratory Findings
To better understand the prevalence of DSA among Shigella in Minnesota, the public health laboratory tested the 80 (86%) available isolates from the 93 shigellosis cases reported in Minnesota in 2014. In addition to the 14 outbreak-associated S. sonnei isolates with DSA, the public health laboratory found DSA in two nonoutbreak S. sonnei isolates and four Shigella flexneri isolates, for a total of 20 (25%) shigellae with DSA in Minnesota in 2014. Patients infected with Shigella with DSA had a median age of 38 years (range = 19-64 years), 18 (90%) were male, and nine (45%) were known to be infected with HIV. Among 16 male patients who provided travel information, none reported recent international travel; two female patients reported travel to Asia.
MSM in the United States and abroad appear to be at greater risk for shigellosis with DSA (10). MSM can protect themselves and others from shigellosis by washing hands before preparing food or eating and after using the toilet; refraining from swimming for 1 week after recovering from shigellosis; avoiding sex while they or their partners have diarrhea and for a few weeks after recovering from shigellosis; washing hands, genitals, and anus before and after sex; and using barriers such as dental dams and gloves during anal rimming and fisting. Clinicians should obtain stool cultures from patients with symptoms of shigellosis and choose treatments, when needed, based on isolate antimicrobial susceptibility profiles. Clinical guidance for the testing and interpretation of azithromycin susceptibility among shigellae is needed to guide patient management. Increasing rates of routine or outbreak-driven PFGE testing of shigellae can help track Shigella strains with DSA. 
